Open AccessIs It Time to Stop Using Single-dose Oral Metronidazole for the Treatment of Trichomoniasis in Women?
Author(s) -
Christina A Muzny,
Saralyn Richter,
Patricia Kissinger
Publication year - 2019
Publication title -
sexually transmitted diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.507
H-Index - 105
eISSN - 1537-4521
pISSN - 0148-5717
DOI - 10.1097/olq.0000000000000959
Subject(s) - medicine , trichomoniasis , metronidazole , regimen , sexually transmitted disease , dosing , human immunodeficiency virus (hiv) , gynecology , antibiotics , virology , syphilis , microbiology and biotechnology , biology
The 2015 Centers for Disease Control Sexually Transmitted Disease treatment guidelines currently recommend a single 2-g dose of oral metronidazole as the preferred regimen for treatment of trichomoniasis in human immunodeficiency virus (HIV)-negative women. Mounting recent evidence has shown that the 7-day oral metronidazole dosing regimen is more efficacious than the single 2-g dose. This commentary reviews the implications associated with these new data and discusses issues surrounding it that should be considered moving forward.